Social Security adds obinutuzumab to the treatment of adults with active lupus nephritis
Resolution No. 715-2026-D.G. extends the drug's use to rheumatology and nephrology and orders purchasing provisions to prevent shortages.

Panama's Social Security Fund (CSS) issued Resolution No. 715-2026-D.G. of October 21, 2026, published in Official Gazette No. 30656 of November 19, 2026, which amends its Catalog of Goods and Services for the item obinutuzumab 1000 mg, intravenous solution. The drug, added in 2023 for hematology only, is now restricted to hematology, rheumatology and nephrology.
Its first provision keeps the original indication, for patients with follicular non-Hodgkin lymphoma who did not respond to rituximab or progressed during or after that treatment, and adds a new one: add-on therapy to standard treatment for adults with active class III or IV lupus nephritis, with or without concomitant class V. The second and third provisions order both changes recorded in the catalog.
The change responded to requests from the Rheumatology Service of the Dr. Arnulfo Arias Madrid Hospital Complex and the Nephrology Service of Ciudad de la Salud, reviewed by the Institutional Pharmacotherapy Commission in sessions in July, August and September 2026. According to the recitals, the commission cited clinical studies showing better results than standard therapy in preventing progression to end-stage kidney disease. The commission's recommendations describe the indication as second-line treatment, although the operative text does not repeat that wording.
On costs, the recitals estimate B/.4,550 per patient for the induction phase and B/.8,190 for the full three-year regimen, compared with B/.22,320 to B/.30,000 per patient per year for hemodialysis. The commission calculates that the investment pays off if 15% of treated patients avoid reaching end-stage chronic kidney disease. For the drug's supplier, which according to the resolution already has a technical sheet, sanitary registration and a bidder, the expansion could raise institutional demand.
The fourth provision orders the logistics, procurement and supply directorates to plan for consumption and stock to prevent shortages. The effect for patients will depend on those purchases and on the biologics protocols required by the commission. The resolution does not estimate how many patients could receive the treatment each year. Nexo Capital will follow the purchase of the drug for its new indication.
Research assisted by Sentinel, with editorial verification of official sources. Discover Legislat.ai